WO2005089780A1 - Composition pour lutter contre le virus du sida et méthode pour désactiver sélectivement les cellules infectées par le virus. - Google Patents

Composition pour lutter contre le virus du sida et méthode pour désactiver sélectivement les cellules infectées par le virus. Download PDF

Info

Publication number
WO2005089780A1
WO2005089780A1 PCT/JP2005/004977 JP2005004977W WO2005089780A1 WO 2005089780 A1 WO2005089780 A1 WO 2005089780A1 JP 2005004977 W JP2005004977 W JP 2005004977W WO 2005089780 A1 WO2005089780 A1 WO 2005089780A1
Authority
WO
WIPO (PCT)
Prior art keywords
virus
cells
antiviral
infected
infected cells
Prior art date
Application number
PCT/JP2005/004977
Other languages
English (en)
Japanese (ja)
Inventor
Keiji Umeda
Taro Shirakawa
Katsunobu Sakai
Yositaka Nadachi
Takehiko Fujino
Original Assignee
Umeda Jimusho Ltd.
Institute Of Rheological Function Of Food Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Umeda Jimusho Ltd., Institute Of Rheological Function Of Food Co., Ltd. filed Critical Umeda Jimusho Ltd.
Priority to JP2006511247A priority Critical patent/JPWO2005089780A1/ja
Publication of WO2005089780A1 publication Critical patent/WO2005089780A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an anti-AIDS virus composition and a method for selectively inactivating virus-infected cells.
  • the present invention relates to an antiviral composition exhibiting an excellent antiviral action against an AIDS virus or the like, and more particularly, to a virus-infected cell infected with a virus such as an AIDS virus.
  • the present invention relates to an antiviral composition having an inactivating function, a functional food to which the antiviral property is added, and an antiviral drug.
  • INDUSTRIAL APPLICABILITY The present invention has an effect of selectively inactivating and killing virus-infected cells in a living cell system in a technical field such as an antiviral preparation applied to a viral disease caused by infection of various viruses such as an AIDS virus.
  • the present invention provides an antiviral composition and a use thereof. For example, the present invention selectively inactivates AIDS virus-infected cells, viral cancer cells, etc., and prevents, treats, and functional foods for these diseases. It is intended to provide useful new drugs and functional foods.
  • Patent Document 1 Japanese Patent Laid-Open No. 5-294838
  • Patent Document 2 Japanese Patent Application Laid-Open No. 2002-293803
  • the present inventors have considered in view of the above-mentioned prior art that prevention and treatment of viral infectious diseases caused by various viruses such as the AIDS virus, which is low in cost and highly safe, can be performed.
  • the new eodo supply system developed by the present inventors for virus-infected cells using eodo ions.
  • the present inventors have found that the intended purpose can be achieved, and have conducted further studies to complete the present invention.
  • the present invention provides a specific antiviral effect of selectively inactivating virus-infected cells by utilizing an eodo-supply system using oodoion in virus-infected cells such as AIDS virus-infected cells. It is an object of the present invention to provide a novel antiviral composition, a functional food containing the antiviral composition, an antiviral drug, and the like.
  • the present invention for solving the above-mentioned problems includes the following technical means.
  • An antiviral composition having an action to selectively inactivate virus-infected cells, characterized by containing as an active ingredient an ore ion or a compound that produces an ore ion.
  • a functional food having an antiviral function wherein the antiviral composition according to the above (1) or (2) is blended to add an antiviral function.
  • An antiviral drug having an action of selectively inactivating virus-infected cells comprising the antiviral composition according to (1) or (2).
  • the virus (1Z2I) acts to selectively inactivate and kill virus-infected cells.
  • a method for selectively inactivating virus-infected cells comprising:
  • the antiviral composition of the present invention is characterized in that it contains, as an active ingredient, an ode ion or a compound that generates an ode ion. Ode (1Z2I) production to supply specifically to cell lines to produce eodo (1Z2I) in virus-infected cells-
  • the present invention provides the following novel findings discovered by the present inventors; (1) generation of eaves on the anode side due to electrolysis of ionic ion water; ⁇ ⁇ [ ⁇ ⁇ ] ⁇ 1 ⁇ 2 ⁇ , (2) live cells
  • the distribution center of normal cells is neutral ⁇ 0, and the distribution center of virus-infected cells is on the minus side.
  • ⁇ infectious hematopoietic necrosis virus that infects salmon
  • the mode ion has been found to be deelectronized to produce eodes because it has an environment similar to (1) above, and (4) the inodes in infected cells inactivate viruses or cells. It was created based on the fact that it was recognized.
  • FIG. 1 shows an example of an apparatus used for carrier-free electrophoresis of living cells of a living tissue.
  • a is the anode (platinum)
  • b is the connection of the anode terminal
  • c is the force sword (platinum)
  • e is the filter paper
  • f is the filter paper that prevents cell diffusion
  • g is the buffer
  • h is the buffer.
  • a magnetic ferrite rubber part for mounting means for dividing into two parts, i is a plastic plate used for separating the apparatus into electrophoresis.
  • the device was controlled at 15 ° C for fish cells or 37 ° C for animal cells. The arrow indicates the position of the cross section.
  • FIG. 2 shows an electrophoretic diagram of virus-infected RTG-2 cells (cultivable cells collected from germ-line glands of -mouth trout and cultured host cells of the IHN virus or the like). These are electropherograms of virus-infected RTG-2 cells.
  • electrophoresis was performed at 15 ° C in MEM one day after infection with the IHN virus. Electrophoresis was performed 3 days later.
  • C g-strophantin or sodium azide was added 5 days after the infection and electrophoresis was performed in MEM.
  • D electrophoresis was performed 5 days after the infection.
  • E the cells were electrophoresed at 15 ° C in MEM.
  • FIG. 3 shows electropherograms of live RTG-2 cells and CHSE-214 cells (culturable cells collected from trout (masunosuke) and host culture cells of IHN virus or the like). These cells show that 107 Zlml of RTG-2 cells or CHSE-214 cells were calored in the center of the electrophoresis apparatus.
  • electrophoresis (20 mA, 15 minutes in DC) was performed with EBSS at pH pH 7.0. The results of electrophoresis at 0 are shown.
  • examples of ⁇ and Nal are given as examples of ⁇ or Nal as a compound that produces ⁇ or ion, but any compound that produces ⁇ ⁇ can be used as long as it is not limited to these. .
  • the antiviral activity can be further enhanced by combining a polyphenol compound such as humic acid, tea power techin, or the like with the anode.
  • a polyphenol compound such as humic acid, tea power techin, or the like
  • an antiviral composition can be prepared by combining these compounds with, for example, a pharmaceutically acceptable carrier.
  • a functional food having an antiviral function can be obtained.
  • the antiviral composition can be used as an antiviral drug.
  • sodium eodo-sodium Z polyphenols such as tea catechin or humic acid
  • a net charge in carrier-free electrophoresis of a cell is set as a marker, and a neutral charge is set at a normal point, and a positive / negative charge shift of a neutral point force is calculated.
  • a measure of the metabolic abnormalities of cells it is possible to fractionate sample cells alive using an electrophoresis apparatus and measure their distribution.
  • an active ingredient that controls cell abnormalities can be specified. Also
  • Ode ions or olude ions to be incorporated into the antiviral composition of the present invention The amount of the compound to be produced is as long as the desired effect of the present invention is exhibited.
  • the antiviral composition of the present invention may contain diluents or excipients such as fillers, bulking agents, binders, humectants, disintegrants, surfactants, and lubricants which are usually used in pharmaceutical preparations. It is prepared using The form of this composition can be selected according to the purpose of treatment, and typical examples include tablets, pills, powders, solutions, suspensions, emulsions, granules, capsules, and injections (solutions). , Suspending agents, etc.).
  • composition of the present invention may contain conventional additives such as vitamins, hormonal agents, pharmacologic agents such as amino acids, surfactants, pigments, dyes, pigments, fragrances, ultraviolet absorbers, humectants, and humectants.
  • vitamins, hormonal agents, pharmacologic agents such as amino acids, surfactants, pigments, dyes, pigments, fragrances, ultraviolet absorbers, humectants, and humectants.
  • a tackifier, an antioxidant, a sequestering agent, a pH adjuster, and the like can be arbitrarily added as necessary.
  • examples of the carrier include excipients such as glucose, lactose, starch, cocoa butter, hydrogenated vegetable oil, kaolin, and talc; binders such as gum arabic, tragacanth, gelatin, and ethanol; laminaran; And disintegrating agents such as agar.
  • the solvents, emulsions and suspensions are preferably sterile and isotonic with blood.
  • water, ethyl alcohol, propylene glycol, polyoxyethylene sorbitan fatty acid ester and the like can be used as the diluent.
  • the compounding method and administration method of the antiviral composition or the drug thereof of the present invention are not particularly limited, and are compounded by a method according to various formulation forms, patient age, gender and other conditions, degree of disease, and the like. Or administered. For example, tablets, pills, solutions, suspensions, emulsions, granules, and capsules are orally administered.
  • the dose of the preparation of the present invention is appropriately selected depending on the usage, age of the patient, gender, other conditions, the degree of the disease, and the like.In general, the amount of the active ingredient compound is expressed as It is preferred that the amount be about 11 to 200 mg. In addition, it is preferable that the preparation is usually administered in 1 to 3 divided doses.
  • the antiviral composition of the present invention exhibits an excellent antiviral effect of selectively inactivating virus-infected cells, and has extremely low toxicity and excellent safety. is there. Further, the active ingredient such as the antiviral composition of the present invention is excellent in solubility in water and excellent in absorbability of intestinal tract. Further, the antiviral composition of the present invention And the like have the effect of selectively inactivating virus-infected cells, so that their formulation or administration can be extremely small.
  • the shape, form and the like are not particularly limited, and they can be arbitrarily designed.
  • a novel antiviral composition effective for prevention and treatment of viral infections caused by various viruses such as AIDS virus
  • an antiviral function is added.
  • (3) can provide an antiviral drug effective against infectious diseases caused by viruses such as AIDS virus, and (4) can provide virus-infected cells.
  • New evil (1Z2I) that can be selectively deactivated
  • the present invention will be specifically described by an IHN virus infection suppression test.
  • a MEM medium minimum essential nutrient medium containing 1 ⁇ g / ml3 ⁇ 4V and 10 ⁇ g Zml of tea catechin was inoculated with 2 cells of RTG-2 cells derived from dimasu, and 0.1 I / cell was added to each cell.
  • the cells were infected with the HN virus (moiO.1) and cultured at 15 ° C and pH 7.2 for 5 to 10 days. After the culture, the number of viruses (virus titer TCID Zml) was measured using the culture supernatant. That
  • a MEM medium minimum essential nutrient medium containing 1 ⁇ gZml of humic acid and 10 ⁇ gZml of humic acid was inoculated with RTG-2 cultured cells derived from dimasu, and 0.01 IHN / cell was further added.
  • the virus (moiO.01) was infected and cultured at 15 ° C., pH 7.2 for 7 days. After the culture, the number of viruses (virus titer TCID / ml) was measured using the culture supernatant. Table 2 shows the results.
  • Two 60-liter aquariums contain 220 juvenile salmon trout with an average weight of 0.5 g, and feed humic acid and humic acid to one juvenile while supplying breeding water (groundwater) at 10 ° C at a rate of 2 liters Z.
  • the Nal-mixed diet was fed, while the other fry were fed a normal diet without them as a control.
  • Mixing 5 mg of humic acid and 50 mg of NaI per 100 g of small granular feed and coating with 5 g of feed oil prevents dissolution and diffusion of reagents into water.
  • a solution containing the IHN virus (virus solution) was adjusted through a micropump to a virus count (virus titer) of 100 TCID Zml in breeding water, bred for 5 days, and infected with the virus.
  • Bait virus count
  • Two 60-liter aquariums hold 220 juvenile salmon trout with an average weight of 0.3 g, and supply humic acid and humic acid to one juvenile while feeding breeding water (groundwater) at 10 ° C at a rate of 2 liters Z.
  • breeding water groundwater
  • the Nal-mixed diet was fed, while the other fry were fed a normal diet without them as a control.
  • Mixing 5 mg of humic acid and 50 mg of NaI per 100 g of small granular feed and coating with 5 g of feed oil prevents dissolution and diffusion of reagents into water.
  • a solution containing the IHN virus (virus solution) was adjusted through a micropump to a virus count (virus titer) of 100 TCID Zml in breeding water, bred for 5 days, and infected with the virus.
  • Two 60-liter aquariums contain 220 fish salmon fry, averaging 0.6-0.9 g in weight, and feed breeding water (groundwater) at 10 ° C at a rate of 2 liters Z to one fry. Food mixed with humic acid and Nal was not mixed with the other fry as a control! Normal feed was given. A mixture of 10 mg of humic acid and NallOmg per 100 g of small granular feed was coated with 5 g of feed oil to prevent the reagent from dissolving and diffusing into water. A solution containing IHN virus (virus solution) is passed through a micropump and the number of viruses (virus titer) 100TCID
  • a toxicity test was performed.
  • Two 60-liter aquariums contain 220 fish salmon fry, averaging 0.3 g in weight, and feed breeding water (groundwater) at 10 ° C at a rate of 2 liters Z while humic acid and The Nal-mixed diet was given, while the other fry were given normal diet without control as a control.
  • Figure 7 shows the results. You.
  • the cells were added after being adjusted (PH 7.4) with a culture medium, and further inoculated with an avian influenza virus solution whose virus titer had been measured in advance, and cultured at 37 ° C for 3-5 days.
  • CPE Cytopathic effect
  • Test Example 9 A microplate is inoculated with 30 ⁇ L of chicken fetal fibroblast cell suspension X 10 5 cells Zml), and the cell culture medium is adjusted to a prescribed concentration of Nal and green tea catechin (main component: epigallocatechin gallate). 37. Adjusted pH (pH 7.4) and spiked, then inoculated with a solution of Avian Newcastle disease virus whose virus titer had been measured in advance. C. The cells were cultured for 35 days.
  • CPE Cytopathic effect
  • a microplate is inoculated with 30 ⁇ L / well of MDBK cell suspension (1 ⁇ 10 5 cells Zml) of Nishi and green tea catechin (main component: epigallocatechin gallate) at a specified concentration.
  • Cell culture medium pH 7.4
  • a microplate is inoculated with 30 L / well of a feline renal fibroblast suspension (1 ⁇ 10 5 cells / ml), and Nal and green tea catechin (main component: epigallocatechin gallate) are in a prescribed concentration.
  • the cells were adjusted with cell culture medium (PH 7.4), added, and inoculated with a feline virulent virus solution whose virus titer had been measured in advance, and cultured at 37 ° C for 3-5 days.
  • CPE Cytopathic effect
  • the present invention relates to an antiviral composition and the like, and according to the present invention, a novel antiviral composition which is extremely effective in preventing and treating infectious diseases caused by viruses such as AIDS virus.
  • Functional foods having antiviral functions, antiviral preparations, etc. can be manufactured and provided. It is possible to provide a novel antiviral drug having an action of selectively inactivating virus-infected cells.
  • a functional food to which an anti-HIV virus activity is added can be provided.
  • Elucidation of the mechanism of cell death in various virus-infected cells and the pathogenesis of new virus infections can be achieved by utilizing the principle of the present invention, which uses the "degeneration system using eodoion in virus-infected cells". It can contribute to the establishment of an evaluation method. Since the antiviral preparation of the present invention is inexpensive and highly safe, it is possible to quickly and urgently respond to and contribute to AIDS relief activities in South Africa and the like by using the antiviral preparation. it can. Brief Description of Drawings
  • FIG. 1 shows a top view and a cross-sectional view of an electrophoresis apparatus used in a test example of the present invention.
  • FIG. 2 shows an electrophoretogram of virus-infected RTG- 2 cells.
  • FIG. 3 shows electropherograms of RTG-2 cells and CHSE-214 cells.
  • FIG. 4 shows the results of an oral administration test to juvenile salmon in Test Example 4.
  • FIG. 5 shows the results of an oral administration test to juvenile salmon trout in Test Example 5.
  • FIG. 6 shows the results of an oral administration test to juvenile salmon trout in Test Example 6.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Une composition antivirale ayant pour effet de désactiver sélectivement les cellules infectées par le virus qui comprend, comme agent actif, un ion iodure ou un composé libérant l’ion iodure ; un nutriment fonctionnel qui contient la composition antivirale décrite plus haut et ayant ainsi une fonction antivirale qui lui est transmise; et un remède antiviral comprenant la composition antivirale décrite plus haut et ayant pour effet de désactiver sélectivement les cellules infectées par le virus. Ainsi on tente d’apporter une nouvelle composition antivirale et ayant une fonction de désactivation sélective des cellules infectées par le SIDA, des cellules cancéreuses virales, etc.
PCT/JP2005/004977 2004-03-18 2005-03-18 Composition pour lutter contre le virus du sida et méthode pour désactiver sélectivement les cellules infectées par le virus. WO2005089780A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2006511247A JPWO2005089780A1 (ja) 2004-03-18 2005-03-18 抗エイズウイルス性組成物及びウイルス感染細胞の選択的不活化方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-079311 2004-03-18
JP2004079311 2004-03-18

Publications (1)

Publication Number Publication Date
WO2005089780A1 true WO2005089780A1 (fr) 2005-09-29

Family

ID=34993438

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/004977 WO2005089780A1 (fr) 2004-03-18 2005-03-18 Composition pour lutter contre le virus du sida et méthode pour désactiver sélectivement les cellules infectées par le virus.

Country Status (2)

Country Link
JP (1) JPWO2005089780A1 (fr)
WO (1) WO2005089780A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042587A1 (fr) * 2010-09-27 2012-04-05 中村　博 Aliment diététique et médicament contenant de l'iodure d'hydrogène et leur procédé de fabrication

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03101623A (ja) * 1989-09-14 1991-04-26 Mitsui Norin Kk インフルエンザウィルス感染予防剤
JPH03141220A (ja) * 1989-10-26 1991-06-17 Tsumura & Co 抗レトロウイルス剤
JPH06502413A (ja) * 1990-10-12 1994-03-17 シェイマン　ファーマシューティカルズ，インコーポレーテッド 抗ウイルス活性をもつプロアントシアニジンポリマーおよびその製造法
JPH06172192A (ja) * 1992-12-10 1994-06-21 Masaya Ootsuka 膣および口腔粘膜用水性消毒剤
JPH11147806A (ja) * 1997-11-13 1999-06-02 Nippon Tenganyaku Kenkyusho:Kk ヒト免疫不全ウィルス殺ウィルス剤
WO2000006202A1 (fr) * 1998-07-29 2000-02-10 Apa Praha, S.R.O. Medicament virocide contenant de l'iode
WO2002047493A2 (fr) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Compositions de composes destinees a la promotion de la sante
JP2004315470A (ja) * 2003-04-18 2004-11-11 Ain Seiyaku Kk ヨウ化ナトリウム含有製剤
JP2004352642A (ja) * 2003-05-29 2004-12-16 Meiji Seika Kaisha Ltd ウイルス感染症予防剤

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03101623A (ja) * 1989-09-14 1991-04-26 Mitsui Norin Kk インフルエンザウィルス感染予防剤
JPH03141220A (ja) * 1989-10-26 1991-06-17 Tsumura & Co 抗レトロウイルス剤
JPH06502413A (ja) * 1990-10-12 1994-03-17 シェイマン　ファーマシューティカルズ，インコーポレーテッド 抗ウイルス活性をもつプロアントシアニジンポリマーおよびその製造法
JPH06172192A (ja) * 1992-12-10 1994-06-21 Masaya Ootsuka 膣および口腔粘膜用水性消毒剤
JPH11147806A (ja) * 1997-11-13 1999-06-02 Nippon Tenganyaku Kenkyusho:Kk ヒト免疫不全ウィルス殺ウィルス剤
WO2000006202A1 (fr) * 1998-07-29 2000-02-10 Apa Praha, S.R.O. Medicament virocide contenant de l'iode
WO2002047493A2 (fr) * 2000-12-16 2002-06-20 Aventis Pharma Deutschland Gmbh Compositions de composes destinees a la promotion de la sante
JP2004315470A (ja) * 2003-04-18 2004-11-11 Ain Seiyaku Kk ヨウ化ナトリウム含有製剤
JP2004352642A (ja) * 2003-05-29 2004-12-16 Meiji Seika Kaisha Ltd ウイルス感染症予防剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Sakanabyo Virus Taisaku Shiken.", HOKKAIDORITSU SUISAN FUKAJO JIGYO SEISEKISHO., vol. 1999, 31 March 2001 (2001-03-31), pages 219, XP002992623 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012042587A1 (fr) * 2010-09-27 2012-04-05 中村　博 Aliment diététique et médicament contenant de l'iodure d'hydrogène et leur procédé de fabrication

Also Published As

Publication number Publication date
JPWO2005089780A1 (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
Quinn The effectiveness, in vitro, of miconazole and keteconazole combined with tissue conditioners in inhibiting the growth of Candida albicans
ES2312884T3 (es) Composiciones antivirales que comprenden derivados de acido fenilacetico.
PT95827B (pt) Processo para a preparacao de composicoes farmaceuticas para combater retrovirus, contendo como ingredientes activos acidos carboxilicos com enxofre
SK138597A3 (en) A pharmaceutical composition containing n-chlorophenylcarbamates, n-chlorophenylthiocarbamates and n-phosphonoglycine derivatives for inhibiting the growth of cancers and viruses in mammals
JPH05504548A (ja) インターロイキン―２とヒスタミン、その類似体又はｈ↓２―受容体アゴニストを含む抗腫瘍性製剤
JP6444515B2 (ja) タウリンのコロナウイルス属及び／又はロタウイルス属のウィルスにより引き起こされる疾患の予防及び／又は治療における応用
BRPI0913889B1 (pt) uso de nifurtimox e composição compreendendo o referido composto para o combate da giardiose
KR20000038352A (ko) 녹차 카테킨을 유효성분으로하는 여성 자궁경부암 예방 또는치료제
Johnkennedy et al. Alterations in biochemical parameters of Wister rats administered with sulfadoxine and pyrimethamine (Fansidar R)
EP4074310A1 (fr) Agent pour traiter des infections par coronavirus, rétrovirus et l'hépatite c
WO2005089780A1 (fr) Composition pour lutter contre le virus du sida et méthode pour désactiver sélectivement les cellules infectées par le virus.
CZ295765B6 (cs) Léčebný přípravek s virucidním účinkem
JP6667792B2 (ja) 抗癌剤の製造方法、抗癌剤及び医薬
Akinrotimi et al. Effects of anaesthetics on metabolic enzyme activities in African catfish, Clarias gariepinus (Burchell, 1822).
JPH06199697A (ja) 抗ウイルス・抗菌・殺菌剤
EP1814566B1 (fr) Traitement ou prevention d'infections virales hemorragiques au moyen de composes immunomodulateurs
RU2452498C2 (ru) Способ приготовления противотуберкулезного лекарственного препарата
JP2004315470A (ja) ヨウ化ナトリウム含有製剤
RU2316320C1 (ru) Противовирусное средство
JP4629964B2 (ja) ウシの消化器疾患治療剤
KR20090058423A (ko) 소디움 메타아르세나이트를 함유하는 ｃ형 바이러스성 간염치료용 조성물
EP0391224B1 (fr) Médicaments et leurs utilisations pour le traitement des parasitoses
NL8902526A (nl) In de dierenfokkerij bruikbare, het enzym lysosime bevattende, en vitamine houdende preparaat en werkwijze voor de bereiding ervan.
Samour et al. Therapeutic management of Babesia shortii infection in a peregrine falcon (Falco peregrinus)
JPH0748279A (ja) 後天性免疫不全症候群の治療法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2006511247

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase